Impact of MYC in regulation of tumor cell metabolism

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1849, Issue 5, 2015, Pages 563-569

  Wahlström, Therese ^a   Arsenian Henriksson, Marie ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer; Metabolic reprogramming; Metabolism; Mitochondria; MYC

Indexed keywords

GLUTAMINE; PROTO-ONCOGENE PROTEINS C-MYC;

CELL PROLIFERATION; GENETICS; GENOMIC INSTABILITY; GLYCOLYSIS; HUMANS; LIPID METABOLISM; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR MICROENVIRONMENT;

CELL PROLIFERATION; GENOMIC INSTABILITY; GLUTAMINE; GLYCOLYSIS; HUMANS; LIPID METABOLISM; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR MICROENVIRONMENT;

EID: 84939881422     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2014.07.004     Document Type: Review

References (104)

1. Diolaiti D., McFerrin L., Carroll P.A., Eisenman R.N. Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis. Biochim. Biophys. Acta 2014, 14:122-129.
2. Henriksson M., Luscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv. Cancer Res. 1996, 68:109-182.
3. Eberhardy S.R., Farnham P.J. c-Myc mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism. J. Biol. Chem. 2001, 276:48562-48571.
4. Rahl P.B., Lin C.Y., Seila A.C., Flynn R.A., McCuine S., Burge C.B., Sharp P.A., Young R.A. c-Myc regulates transcriptional pause release. Cell 2010, 141:432-445.
5. Tu W.B., Helander S., Pilstal R., Hickman K.A., Lourenco C., Jurisica I., Raught B., Wallner B., Sunnerhagen M., Penn L.Z. Myc and its interactors take shape. Biochim. Biophys. Acta 2015, 1849(5):469-483.
6. Cowling V.H., Cole M.D. Mechanism of transcriptional activation by the Myc oncoproteins. Semin. Cancer Biol. 2006, 16:242-252.
7. Lin C.Y., Loven J., Rahl P.B., Paranal R.M., Burge C.B., Bradner J.E., Lee T.I., Young R.A. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012, 151:56-67.
8. Nie Z., Hu G., Wei G., Cui K., Yamane A., Resch W., Wang R., Green D.R., Tessarollo L., Casellas R., Zhao K., Levens D. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012, 151:68-79.
9. Dang C.V., O'Donnell K.A., Zeller K.I., Nguyen T., Osthus R.C., Li F. The c-Myc target gene network. Semin. Cancer Biol. 2006, 16:253-264.
10. Luscher B., Vervoorts J. Regulation of gene transcription by the oncoprotein MYC. Gene 2012, 494:145-160.
11. Herkert B., Eilers M. Transcriptional repression: the dark side of myc. Genes Cancer 2010, 1:580-586.
12. Cantor J.R., Sabatini D.M. Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2012, 2:881-898.
13. Dang C.V. Links between metabolism and cancer. Genes Dev. 2012, 26:877-890.
14. Hann S.R., Thompson C.B., Eisenman R.N. c-myc oncogene protein synthesis is independent of the cell cycle in human and avian cells. Nature 1985, 314:366-369.
15. Rabbitts P.H., Watson J.V., Lamond A., Forster A., Stinson M.A., Evan G., Fischer W., Atherton E., Sheppard R., Rabbitts T.H. Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. EMBO J. 1985, 4:2009-2015.
16. Thompson C.B., Challoner P.B., Neiman P.E., Groudine M. Levels of c-myc oncogene mRNA are invariant throughout the cell cycle. Nature 1985, 314:363-366.
17. Bretones G., Delgado M.D., Leon J. Myc and cell cycle control. Biochim. Biophys. Acta 2014, 14:73-83.
18. Meyer N., Penn L.Z. Reflecting on 25years with MYC. Nat. Rev. Cancer 2008, 8:976-990.
19. Vita M., Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin. Cancer Biol. 2006, 16:318-330.
20. Link J.M., Hurlin P.J. The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis. Biochim. Biophys. Acta 2014, 14:122-129.
21. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11:85-95.
22. Gross S., Cairns R.A., Minden M.D., Driggers E.M., Bittinger M.A., Jang H.G., Sasaki M., Jin S., Schenkein D.P., Su S.M., Dang L., Fantin V.R., Mak T.W. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 2010, 207:339-344.
23. Ward P.S., Patel J., Wise D.R., Abdel-Wahab O., Bennett B.D., Coller H.A., Cross J.R., Fantin V.R., Hedvat C.V., Perl A.E., Rabinowitz J.D., Carroll M., Su S.M., Sharp K.A., Levine R.L., Thompson C.B. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
24. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M., Ward P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C., Thompson C.B., Vander Heiden M.G., Su S.M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
25. Jose C., Bellance N., Rossignol R. Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma?. Biochim. Biophys. Acta 2011, 1807:552-561.
26. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
27. Warburg O. On respiratory impairment in cancer cells. Science 1956, 124:269-270.
28. Jones R.G., Thompson C.B. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009, 23:537-548.
29. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7:11-20.
30. Hsu P.P., Sabatini D.M. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134:703-707.
31. Semenza G.L. HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 2010, 20:51-56.
32. Potter V.R. The biochemical approach to the cancer problem. Fed. Proc. 1958, 17:691-697.
33. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
34. Newsholme E.A., Crabtree B., Ardawi M.S. The role of high rates of glycolysis and glutamine utilization in rapidly dividing cells. Biosci. Rep. 1985, 5:393-400.
35. Weinberg F., Chandel N.S. Mitochondrial metabolism and cancer. Ann. N. Y. Acad. Sci. 2009, 1177:66-73.
36. Munoz-Pinedo C., El Mjiyad N., Ricci J.E. Cancer metabolism: current perspectives and future directions. Cell Death Dis. 2012, 3:e248.
37. Zaidi N., Swinnen J.V., Smans K. ATP-citrate lyase: a key player in cancer metabolism. Cancer Res. 2012, 72:3709-3714.
38. Lupu R., Menendez J.A. Pharmacological inhibitors of fatty acid synthase (FASN)-catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?. Curr. Pharm. Biotechnol. 2006, 7:483-493.
39. Santos C.R., Schulze A. Lipid metabolism in cancer. FEBS J. 2012, 279:2610-2623.
40. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 2006, 9:230-234.
41. Nieman K.M., Kenny H.A., Penicka C.V., Ladanyi A., Buell-Gutbrod R., Zillhardt M.R., Romero I.L., Carey M.S., Mills G.B., Hotamisligil G.S., Yamada S.D., Peter M.E., Gwin K., Lengyel E. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 2011, 17:1498-1503.
42. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
43. Dang C.V. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb. Perspect. Med. 2013, 3.
44. Dang C.V., Kim J.W., Gao P., Yustein J. The interplay between MYC and HIF in cancer. Nat. Rev. Cancer 2008, 8:51-56.
45. Kim J.W., Gao P., Liu Y.C., Semenza G.L., Dang C.V. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol. Cell. Biol. 2007, 27:7381-7393.
46. Doherty J.R., Yang C., Scott K.E., Cameron M.D., Fallahi M., Li W., Hall M.A., Amelio A.L., Mishra J.K., Li F., Tortosa M., Genau H.M., Rounbehler R.J., Lu Y., Dang C.V., Kumar K.G., Butler A.A., Bannister T.D., Hooper A.T., Unsal-Kacmaz K., Roush W.R., Cleveland J.L. Blocking lactate export by inhibiting the Myc target MCT1 disables glycolysis and glutathione synthesis. Cancer Res. 2014, 74:908-920.
47. Dang C.V., Le A., Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res. 2009, 15:6479-6483.
48. Wise D.R., DeBerardinis R.J., Mancuso A., Sayed N., Zhang X.Y., Pfeiffer H.K., Nissim I., Daikhin E., Yudkoff M., McMahon S.B., Thompson C.B. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:18782-18787.
49. Gao P., Tchernyshyov I., Chang T.C., Lee Y.S., Kita K., Ochi T., Zeller K.I., De Marzo A.M., Van Eyk J.E., Mendell J.T., Dang C.V. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009, 458:762-765.
50. Le A., Lane A.N., Hamaker M., Bose S., Gouw A., Barbi J., Tsukamoto T., Rojas C.J., Slusher B.S., Zhang H., Zimmerman L.J., Liebler D.C., Slebos R.J., Lorkiewicz P.K., Higashi R.M., Fan T.W., Dang C.V. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012, 15:110-121.
51. Murphy T.A., Dang C.V., Young J.D. Isotopically nonstationary 13C flux analysis of Myc-induced metabolic reprogramming in B-cells. Metab. Eng. 2013, 15:206-217.
52. Liu Y.C., Li F., Handler J., Huang C.R., Xiang Y., Neretti N., Sedivy J.M., Zeller K.I., Dang C.V. Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS One 2008, 3:e2722.
53. Mannava S., Grachtchouk V., Wheeler L.J., Im M., Zhuang D., Slavina E.G., Mathews C.K., Shewach D.S., Nikiforov M.A. Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. Cell Cycle 2008, 7:2392-2400.
54. Vazquez A., Markert E.K., Oltvai Z.N. Serine biosynthesis with one carbon catabolism and the glycine cleavage system represents a novel pathway for ATP generation. PLoS One 2011, 6:e25881.
55. Vazquez A., Tedeschi P.M., Bertino J.R. Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors. Cancer Res. 2013, 73:478-482.
56. Ahuja P., Zhao P., Angelis E., Ruan H., Korge P., Olson A., Wang Y., Jin E.S., Jeffrey F.M., Portman M., Maclellan W.R. Myc controls transcriptional regulation of cardiac metabolism and mitochondrial biogenesis in response to pathological stress in mice. J. Clin. Invest. 2010, 120:1494-1505.
57. Graves J.A., Wang Y., Sims-Lucas S., Cherok E., Rothermund K., Branca M.F., Elster J., Beer-Stolz D., Van Houten B., Vockley J., Prochownik E.V. Mitochondrial structure, function and dynamics are temporally controlled by c-Myc. PLoS One 2012, 7:e37699.
58. Morrish F., Giedt C., Hockenbery D. c-MYC apoptotic function is mediated by NRF-1 target genes. Genes Dev. 2003, 17:240-255.
59. Li F., Wang Y., Zeller K.I., Potter J.J., Wonsey D.R., O'Donnell K.A., Kim J.W., Yustein J.T., Lee L.A., Dang C.V. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol. Cell. Biol. 2005, 25:6225-6234.
60. Zhang H., Gao P., Fukuda R., Kumar G., Krishnamachary B., Zeller K.I., Dang C.V., Semenza G.L. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007, 11:407-420.
61. Kim J., Lee J.H., Iyer V.R. Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS One 2008, 3:e1798.
62. Fogal V., Richardson A.D., Karmali P.P., Scheffler I.E., Smith J.W., Ruoslahti E. Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation. Mol. Cell. Biol. 2010, 30:1303-1318.
63. Koppenol W.H., Bounds P.L., Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 2011, 11:325-337.
64. Liu L., Ulbrich J., Muller J., Wustefeld T., Aeberhard L., Kress T.R., Muthalagu N., Rycak L., Rudalska R., Moll R., Kempa S., Zender L., Eilers M., Murphy D.J. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 2012, 483:608-612.
65. Morrish F., Noonan J., Perez-Olsen C., Gafken P.R., Fitzgibbon M., Kelleher J., VanGilst M., Hockenbery D. Myc-dependent mitochondrial generation of acetyl-CoA contributes to fatty acid biosynthesis and histone acetylation during cell cycle entry. J. Biol. Chem. 2010, 285:36267-36274.
66. Fan Y., Dickman K.G., Zong W.X. Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J. Biol. Chem. 2010, 285:7324-7333.
67. Yuneva M.O., Fan T.W., Allen T.D., Higashi R.M., Ferraris D.V., Tsukamoto T., Mates J.M., Alonso F.J., Wang C., Seo Y., Chen X., Bishop J.M. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 2012, 15:157-170.
68. Krycer J.R., Sharpe L.J., Luu W., Brown A.J. The Akt-SREBP nexus: cell signaling meets lipid metabolism. Trends Endocrinol. Metab. 2010, 21:268-276.
69. Yang Y.A., Han W.F., Morin P.J., Chrest F.J., Pizer E.S. Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp. Cell Res. 2002, 279:80-90.
70. Loven J., Orlando D.A., Sigova A.A., Lin C.Y., Rahl P.B., Burge C.B., Levens D.L., Lee T.I., Young R.A. Revisiting global gene expression analysis. Cell 2012, 151:476-482.
71. Zeller K.I., Jegga A.G., Aronow B.J., O'Donnell K.A., Dang C.V. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol. 2003, 4:R69.
72. Zirath H., Frenzel A., Oliynyk G., Segerstrom L., Westermark U.K., Larsson K., Munksgaard Persson M., Hultenby K., Lehtio J., Einvik C., Pahlman S., Kogner P., Jakobsson P.J., Henriksson M.A. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:10258-10263.
73. Muller I., Larsson K., Frenzel A., Oliynyk G., Zirath H., Prochownik E.V., Westwood N.J., Henriksson M.A. Targeting of the MYCN protein with small molecule c-MYC inhibitors. PLoS One 2014, 9:e97285.
74. Edsjo A., Holmquist L., Pahlman S. Neuroblastoma as an experimental model for neuronal differentiation and hypoxia-induced tumor cell dedifferentiation. Semin. Cancer Biol. 2007, 17:248-256.
75. Reilly P.T., Mak T.W. Molecular pathways: tumor cells Co-opt the brain-specific metabolism gene CPT1C to promote survival. Clin. Cancer Res. 2012, 18:5850-5855.
76. Zaugg K., Yao Y., Reilly P.T., Kannan K., Kiarash R., Mason J., Huang P., Sawyer S.K., Fuerth B., Faubert B., Kalliomaki T., Elia A., Luo X., Nadeem V., Bungard D., Yalavarthi S., Growney J.D., Wakeham A., Moolani Y., Silvester J., Ten A.Y., Bakker W., Tsuchihara K., Berger S.L., Hill R.P., Jones R.G., Tsao M., Robinson M.O., Thompson C.B., Pan G., Mak T.W. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. 2011, 25:1041-1051.
77. Yuan J., Minter-Dykhouse K., Lou Z. A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J. Cell Biol. 2009, 185:203-211.
78. Houtkooper R.H., Pirinen E., Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat. Rev. Mol. Cell Biol. 2012, 13:225-238.
79. Sebastian C., Satterstrom F.K., Haigis M.C., Mostoslavsky R. From sirtuin biology to human diseases: an update. J. Biol. Chem. 2012, 287:42444-42452.
80. Dang C.V. Therapeutic targeting of Myc-reprogrammed cancer cell metabolism. Cold Spring Harb. Symp. Quant. Biol. 2011, 76:369-374.
81. Yuneva M., Zamboni N., Oefner P., Sachidanandam R., Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J. Cell Biol. 2007, 178:93-105.
82. Shim H., Chun Y.S., Lewis B.C., Dang C.V. A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:1511-1516.
83. Qing G., Li B., Vu A., Skuli N., Walton Z.E., Liu X., Mayes P.A., Wise D.R., Thompson C.B., Maris J.M., Hogarty M.D., Simon M.C. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell 2012, 22:631-644.
84. Robinson M.M., McBryant S.J., Tsukamoto T., Rojas C., Ferraris D.V., Hamilton S.K., Hansen J.C., Curthoys N.P. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem. J. 2007, 406:407-414.
85. Ahluwalia G.S., Grem J.L., Hao Z., Cooney D.A. Metabolism and action of amino acid analog anti-cancer agents. Pharmacol. Ther. 1990, 46:243-271.
86. Ovejera A.A., Houchens D.P., Catane R., Sheridan M.A., Muggia F.M. Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice. Cancer Res. 1979, 39:3220-3224.
87. Hidalgo M., Rodriguez G., Kuhn J.G., Brown T., Weiss G., MacGovren J.P., Von Hoff D.D., Rowinsky E.K. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies. Clin. Cancer Res. 1998, 4:2763-2770.
88. Qing G., Skuli N., Mayes P.A., Pawel B., Martinez D., Maris J.M., Simon M.C. Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha. Cancer Res. 2010, 70:10351-10361.
89. Weiss W.A., Aldape K., Mohapatra G., Feuerstein B.G., Bishop J.M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997, 16:2985-2995.
90. Guth P.S., Risey J., Briner W., Blair P., Reed H.T., Bryant G., Norris C., Housley G., Miller R. Evaluation of amino-oxyacetic acid as a palliative in tinnitus. Ann. Otol. Rhinol. Laryngol. 1990, 99:74-79.
91. Wang J.B., Erickson J.W., Fuji R., Ramachandran S., Gao P., Dinavahi R., Wilson K.F., Ambrosio A.L., Dias S.M., Dang C.V., Cerione R.A. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010, 18:207-219.
92. Li B., Simon M.C. Molecular pathways: targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer. Clin. Cancer Res. 2013, 19:5835-5841.
93. Le A., Cooper C.R., Gouw A.M., Dinavahi R., Maitra A., Deck L.M., Royer R.E., Vander Jagt D.L., Semenza G.L., Dang C.V. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:2037-2042.
94. Shim H., Dolde C., Lewis B.C., Wu C.S., Dang G., Jungmann R.A., Dalla-Favera R., Dang C.V. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:6658-6663.
95. Fantin V.R., St-Pierre J., Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9:425-434.
96. Xie H., Valera V.A., Merino M.J., Amato A.M., Signoretti S., Linehan W.M., Sukhatme V.P., Seth P. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol. Cancer Ther. 2009, 8:626-635.
97. Wang Z.Y., Loo T.Y., Shen J.G., Wang N., Wang D.M., Yang D.P., Mo S.L., Guan X.Y., Chen J.P. LDH-A silencing suppresses breast cancer tumorigenicity through induction of oxidative stress mediated mitochondrial pathway apoptosis. Breast Cancer Res. Treat. 2012, 131:791-800.
98. Nilsson L.M., Forshell T.Z., Rimpi S., Kreutzer C., Pretsch W., Bornkamm G.W., Nilsson J.A. Mouse genetics suggests cell-context dependency for Myc-regulated metabolic enzymes during tumorigenesis. PLoS Genet. 2012, 8:e1002573.
99. Menssen A., Hermeking H. Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:6274-6279.
100. Bonnet S., Archer S.L., Allalunis-Turner J., Haromy A., Beaulieu C., Thompson R., Lee C.T., Lopaschuk G.D., Puttagunta L., Bonnet S., Harry G., Hashimoto K., Porter C.J., Andrade M.A., Thebaud B., Michelakis E.D. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11:37-51.
101. Pollak M.N. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2012, 2:778-790.
102. Zhang X., Fryknas M., Hernlund E., Fayad W., De Milito A., Olofsson M.H., Gogvadze V., Dang L., Pahlman S., Schughart L.A., Rickardson L., D'Arcy P., Gullbo J., Nygren P., Larsson R., Linder S. Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nat. Commun. 2014, 5:3295.
103. Miltenberger R.J., Sukow K.A., Farnham P.J. An E-box-mediated increase in cad transcription at the G1/S-pjase boundary issuppressedby inhibitory c-Myc mutants. Mol. Cell. Biol. 1995, 15(5):2527-2535.
104. Bello-Fernandez C., Packman G., Cleveland J.L. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl. Acad. Sci. U.S.A. 1993, 90(16):7804-7808.